Home
/
GUIDED THERAPEUTICS INC
/
Financials
/
Quarterly
GUIDED THERAPEUTICS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that GUIDED THERAPEUTICS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$60.0K
Nov 13, 2025
Q2
2025
Jun 30, 2025
$117.0K
Aug 14, 2025
Q1
2025
Mar 31, 2025
$0
May 15, 2025
Q3
2025
Sep 30, 2024
$0
Nov 13, 2025
Q2
2025
Jun 30, 2024
$0
Aug 14, 2025
Q1
2025
Mar 31, 2024
$6.0K
May 15, 2025
Q3
2024
Sep 30, 2023
$0
Nov 14, 2024
Q2
2024
Jun 30, 2023
$44.0K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$22.0K
May 14, 2024
Q3
2023
Sep 30, 2022
$3.0K
Nov 13, 2023
Q2
2023
Jun 30, 2022
$5.0K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$5.0K
May 15, 2023
Q3
2022
Sep 30, 2021
$19.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$2.0K
Aug 15, 2022
Q1
2022
Mar 31, 2021
$0
May 16, 2022
Q3
2021
Sep 30, 2020
$77.0K
Nov 15, 2021
Q2
2021
Jun 30, 2020
$0
Aug 18, 2021
Q1
2021
Mar 31, 2020
$0
Aug 18, 2021
Q3
2020
Sep 30, 2019
$1.0K
Nov 5, 2020
Q2
2020
Jun 30, 2019
$1.0K
Aug 20, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$4.0K
May 21, 2018
Q3
2017
Sep 30, 2017
$33.0K
Nov 20, 2017
Q1
2018
Mar 31, 2017
$21.0K
May 21, 2018
Q3
2017
Sep 30, 2016
$95.0K
Nov 20, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($742.0K)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($811.0K)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($427)
May 15, 2025
Q3
2025
Sep 30, 2024
($654.0K)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($709.0K)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($402)
May 15, 2025
Q3
2024
Sep 30, 2023
($677.0K)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.56M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($869.0K)
May 14, 2024
Q3
2023
Sep 30, 2022
($1.10M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($926.0K)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($507.0K)
May 15, 2023
Q3
2022
Sep 30, 2021
$68.0K
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.03M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($517.0K)
May 16, 2022
Q3
2021
Sep 30, 2020
$1.58M
Nov 15, 2021
Q2
2021
Jun 30, 2020
($6.77M)
Aug 18, 2021
Q1
2021
Mar 31, 2020
$2.73M
Aug 18, 2021
Q3
2020
Sep 30, 2019
($126.0K)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($2.66M)
Aug 20, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($485.0K)
Nov 13, 2025
Q2
2025
Jun 30, 2025
($763.0K)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($414.0K)
May 15, 2025
Q3
2025
Sep 30, 2024
($561.0K)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($655.0K)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($359.0K)
May 15, 2025
Q3
2024
Sep 30, 2023
($623.0K)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.51M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($843.0K)
May 14, 2024
Q3
2023
Sep 30, 2022
($1.22M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($717.0K)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($443.0K)
May 15, 2023
Q3
2022
Sep 30, 2021
($487.0K)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($561.0K)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($823.0K)
May 16, 2022
Q3
2021
Sep 30, 2020
($153.0K)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($369.0K)
Aug 18, 2021
Q1
2021
Mar 31, 2020
($242.0K)
Aug 18, 2021
Q3
2020
Sep 30, 2019
($188.0K)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($327.0K)
Aug 20, 2020